Olympus shares tumble after FDA warning deepens compliance risks

Traders Union
All News
Financial News
Olympus shares tumble after FDA warning

Highlights

Olympus shares plunged as much as 16.7 per cent in Tokyo after an expanded FDA warning criticised quality management at six factories across the U.S., Japan, and Europe.
The FDA warning increases compliance risks and casts doubt on the pace of Olympus's ongoing turnaround plan, which includes 2,000 job cuts and asset sales.
Analysts at Jefferies highlight that the new FDA letter suggests Olympus's quality issues are systemic, potentially requiring years and more warnings to fully resolve.

FDA warning expands scrutiny of manufacturing controls

As reported by Financial Times, the latest warning from the U.S. Food and Drug Administration criticises Olympus's quality management system after the regulator identified problems at six factories inspected in the U.S., Japan and Europe towards the end of 2025. The company says it will submit a comprehensive response within 15 business days.

Olympus, a leading supplier of medical endoscopes, has been under FDA scrutiny over manufacturing quality since 2022, a process that already resulted in a ban on imports of certain devices into the U.S. Bob White, chief executive of Olympus, says the company takes the concerns in the warning letter seriously and is committed to addressing them with urgency and rigour.

Share-price shock raises pressure on turnaround plan

Investors push Olympus shares down as much as 16.7 per cent in Tokyo on Wednesday before the stock recovers slightly to trade down 13.2 per cent. The move leaves the company on track for its steepest single-day fall since it admitted to an accounting scandal in 2011.

The drop increases pressure on White's broader restructuring effort at the 107-year-old manufacturer. Earlier this year, he said Olympus was using private equity-style tactics to deter potential suitors, including cutting 2,000 jobs, reshaping its regional structure and selling assets to simplify the portfolio.

Olympus shares are down 13.3 per cent since the start of the year, even after a rebound following a sharp fall in February on weaker profit guidance. Jefferies analyst Stephen Barker says the new letter confirms the company's quality issues are systemic and suggests a full resolution is likely to take years rather than quarters, with additional warning letters potentially extending that timeline further.

Our earlier coverage of Malaysia’s post-1MDB accountability debate looked at what happens when controls, audits, and checks and balances break down, and who should be held responsible. It highlighted the growing emphasis on board accountability, stronger whistleblower protection, and a shift in internal auditing toward earlier risk detection rather than post-failure reviews.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.